EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies

Emanuele Monda iD, Gaetano Diana, Francesca Graziani iD, Marta Rubino, Athanasios Bakalakos iD, Ales Linhart, Dominique P Germain iD, Maurizio Scarpa, Elena Biagini iD, Maurizio Pieroni iD, Perry Mark Elliott iD, Giuseppe Limongelli iD

Circulation: Genomic and Precision Medicine · 2023

DOI: 10.1161/circgen.123.004252 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Circulation: Genomic and Precision Medicine, 2023. Verfasst von Emanuele Monda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, Inherited and Rare Cardiovascular Diseases, University of Campania Luigi Vanvitelli, Naples, Italy (E.M…. Hauptthemen laut MEDLINE: Fabry Disease, Stroke. Die Arbeit wurde bisher 23-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The diagnosis of Fabry disease (FD) has relevant implications related to the management. Thus, a clear assignment of GLA variant pathogenicity is crucial. This systematic review and meta-analysis aimed to investigate the prevalence of FD in high-risk populations and newborns and evaluate the impact of different GLA variant classifications on the estimated prevalence of FD. METHODS: We searched the EMBASE and PubMed databases on February 21, 2023. Observational studies evaluating the prevalence of FD and reporting the identified GLA variants were included. GLA variants were re-evaluated for their pathogenicity significance using the American College of Medical Genetics and Genomics criteria and the ClinVar database. The pooled prevalence of FD among different settings was calculated. The study was registered on PROSPERO (CRD42023401663) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. RESULTS: Of the 3941 studies identified, 110 met the inclusion criteria. The pooled prevalence of FD was significantly different according to the clinical setting and criteria used for the pathogenicity assessment. Using the American College of Medical Genetics and Genomics criteria, the pooled prevalence was 1.2% in patients with left ventricular hypertrophy/hypertrophic cardiomyopathy (26 studies; 10 080 patients screened), 0.3% in end-stage renal disease/chronic kidney disease (38 studies; 62 050 patients screened), 0.7% in stroke (25 studies; 15 295 patients screened), 0.7% in cardiac conduction disturbance requiring pacemaker (3 studies; 1033 patients screened), 1.0% in small-fiber neuropathy (3 studies; 904 patients screened), and 0.01% in newborns (15 studies; 11 108 793 newborns screened). The pooled prevalence was different if the GLA variants were assessed using the ClinVar database, and most patients with a discrepancy in the pathogenicity assignment carried 1 of the following variants: p.A143T, p.D313Y, and p.E66Q. CONCLUSIONS: This systematic review and meta-analysis describe the prevalence of FD among newborns and high-risk populations, highlighting the need for a periodic reassessment of the GLA variants in the context of recent clinical, biochemical, and histological data. REGISTRATION: URL: https://crd.york.ac.uk/PROSPERO/ ; Unique identifier: CRD42023401663.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry DiseaseStrokeHumansInfant, Newbornalpha-GalactosidasePrevalenceHypertrophy, Left Ventricular

Stichwörter der Autor:innen

Fabry diseasegalactosidasesglobotriaosylceramidehumansprevalence

Substanzen

alpha-Galactosidase

Autor:innen und Institutionen

  • Department of Translational Medical Sciences, Inherited and Rare Cardiovascular Diseases, University of Campania Luigi Vanvitelli, Naples, Italy (E.M., G.D., M.R., G.L.).
  • Institute of Cardiovascular Science, University College London, United Kingdom (E.M., A.B., P.M., G.L.).
  • Department of Cardiovascular Sciences, IRCCS, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy (F.G.).
  • 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (A.L.).
  • Division of Medical Genetics, APHP Paris-Saclay University, University of Versailles, Montigny-le-Bretonneux, France (D.P.G.).
  • Regional Coordinator Centre for Rare Diseases, University Hospital of Udine, Italy (M.S.).

ORCID-Profile: Emanuele Monda, Francesca Graziani, Athanasios Bakalakos, Dominique P Germain, Elena Biagini, Maurizio Pieroni, Perry Mark Elliott, Giuseppe Limongelli

Zitieren

APA

Monda, E., Diana, G., Graziani, F., Rubino, M., Bakalakos, A., Linhart, A., Germain, D. P., Scarpa, M., Biagini, E., Pieroni, M., Elliott, P. M., & Limongelli, G. (2023). Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.123.004252

Vancouver

Monda E, Diana G, Graziani F, Rubino M, Bakalakos A, Linhart A, et al. Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies. Circulation: Genomic and Precision Medicine. 2023. doi:10.1161/circgen.123.004252

BibTeX
@article{Monda2023,
  author = {Monda, Emanuele and Diana, Gaetano and Graziani, Francesca and Rubino, Marta and Bakalakos, Athanasios and Linhart, Ales and Germain, Dominique P and Scarpa, Maurizio and Biagini, Elena and Pieroni, Maurizio and Elliott, Perry Mark and Limongelli, Giuseppe},
  title = {Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies},
  journal = {Circulation: Genomic and Precision Medicine},
  year = {2023},
  doi = {10.1161/circgen.123.004252}
}
Kostenlos starten →